Recent studies published in The Lancet Diabetes & Endocrinology have examined the efficacy of higher doses of semaglutide, a medication commonly used for weight management. The research indicates that a 7.2 mg dose of semaglutide results in greater weight loss compared to lower doses or a placebo, with participants reporting an average weight loss of 19% versus 16% for the 2.4 mg dose and nearly 4% for the placebo.
The first study involved 1,407 participants with obesity, while the second focused on 512 individuals diagnosed with both obesity and type 2 diabetes. Both trials noted improvements in various health metrics, including waist circumference, blood pressure, and blood sugar levels, particularly among those receiving the higher dose. However, gastrointestinal side effects were reported, although they were generally manageable.
Medical professionals have expressed cautious optimism regarding these findings. Dr. Mir Ali highlighted that while semaglutide is currently the most effective weight-loss medication available, a holistic approach that includes lifestyle changes remains crucial for sustained results. Dr. Dan Azagury noted the potential for significant side effects at higher doses, particularly an increase in skin sensitivity, which warrants further investigation.
It is important to note that the 7.2 mg dosing may fall outside the FDA's recommended usage for semaglutide, as the approved dose is 2.4 mg. This could lead to increased out-of-pocket expenses for patients, as higher doses might not be covered by insurance. Both experts emphasize the necessity of incorporating dietary changes and exercise in conjunction with any pharmacological interventions for effective long-term weight management.